DexCom, Inc. (NASDAQ:DXCM) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of DexCom, Inc. (NASDAQ:DXCM) have been assigned an average rating of “Moderate Buy” from the twenty-one brokerages that are covering the company, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold recommendation, fourteen have given a buy recommendation and three have given a strong buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $98.32.

Several research analysts recently weighed in on DXCM shares. Cfra Research upgraded shares of DexCom to a “hold” rating in a report on Friday, March 21st. Barclays lifted their price objective on shares of DexCom from $90.00 to $93.00 and gave the stock an “equal weight” rating in a research report on Monday, May 5th. Wells Fargo & Company reaffirmed an “overweight” rating on shares of DexCom in a research report on Saturday, March 8th. Citigroup reaffirmed a “buy” rating and issued a $102.00 price objective (up previously from $82.00) on shares of DexCom in a research report on Thursday, May 22nd. Finally, Robert W. Baird lowered their price objective on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research report on Friday, May 2nd.

DexCom Stock Up 1.1%

DexCom stock opened at $86.67 on Friday. DexCom has a fifty-two week low of $57.52 and a fifty-two week high of $118.80. The stock has a market cap of $33.98 billion, a PE ratio of 60.61, a price-to-earnings-growth ratio of 2.30 and a beta of 1.46. The firm’s 50-day simple moving average is $76.38 and its 200 day simple moving average is $79.04. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.01). DexCom had a return on equity of 30.14% and a net margin of 14.29%. The firm had revenue of $1.04 billion for the quarter, compared to analysts’ expectations of $1.02 billion. During the same quarter last year, the firm posted $0.32 earnings per share. The firm’s revenue for the quarter was up 12.5% compared to the same quarter last year. Research analysts predict that DexCom will post 2.03 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Sadie Stern sold 6,184 shares of the company’s stock in a transaction on Tuesday, May 27th. The shares were sold at an average price of $85.11, for a total value of $526,320.24. Following the completion of the sale, the executive vice president now owns 109,621 shares of the company’s stock, valued at approximately $9,329,843.31. This represents a 5.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Michael Jon Brown sold 10,000 shares of the company’s stock in a transaction on Friday, May 23rd. The shares were sold at an average price of $84.28, for a total transaction of $842,800.00. Following the completion of the sale, the executive vice president now directly owns 95,602 shares of the company’s stock, valued at $8,057,336.56. This trade represents a 9.47% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 83,110 shares of company stock valued at $6,103,505 in the last quarter. Corporate insiders own 0.32% of the company’s stock.

Institutional Investors Weigh In On DexCom

Institutional investors have recently added to or reduced their stakes in the company. Congress Asset Management Co. boosted its position in DexCom by 5,456.9% during the 4th quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company’s stock valued at $105,529,000 after buying an additional 1,332,522 shares during the period. Proficio Capital Partners LLC purchased a new stake in DexCom during the 4th quarter valued at $5,812,000. SBI Securities Co. Ltd. purchased a new stake in DexCom during the 4th quarter valued at $49,000. Asset Management One Co. Ltd. boosted its position in DexCom by 3.4% during the 4th quarter. Asset Management One Co. Ltd. now owns 243,375 shares of the medical device company’s stock valued at $19,528,000 after buying an additional 7,901 shares during the period. Finally, MFG Wealth Management Inc. purchased a new stake in DexCom during the 4th quarter valued at $1,574,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.